Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Projected Compound Annual Growth Rate (CAGR) of the Thyroid Eye Disease (TED) Market from 2025 to 2034, and What Factors Influence It?

The market size of thyroid eye disease (TED) has experienced a significant surge in growth recently. Predictions show that it will rise from $2.15 billion in 2024 to $2.30 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. This substantial growth during the historical period is largely driven by factors such as the escalating number of thyroid health issues, an enhanced emphasis on patient-oriented therapy, a heightened demand for aesthetic procedures, a growing prevalence of the disorder, and expanded therapeutic choices for TED.

The market for thyroid eye disease (TED) is projected to experience substantial growth in the coming years, with its value anticipated to reach $2.97 billion by 2029, boasting a compound annual growth rate (CAGR) of 6.6%. This projected upswing during the forecast period is linked to factors such as a rising incidence of Graves’ disease, an increase in financing across diverse industries, growth in healthcare spending, a surge in the application of thyroid hormone replacement therapy, and a heightened occurrence of thyroid disease. The forecast period also indicates key market trends encompassing technological progress, broadening R&D initiatives, the emergence of innovative drugs, enhancements in treatment choices, and the introduction of new surgical procedures.

What Drivers Are Shaping the Growth of the Thyroid Eye Disease (TED) Market?

The burgeoning incidence of thyroid ailments is anticipated to foster the escalation of the thyroid eye disease (TED) market in the future. Thyroid issues are health problems that interfere with the performance of the thyroid gland, causing disruption in hormone regulation and thus bringing about diseases like hypothyroidism, hyperthyroidism, goiter, and thyroid eye disease. The surge in thyroid disorders is stimulated by elements such as escalated iodine consumption, autoimmune disorders, hereditary susceptibility, and increased awareness leading to better detection rates. Thyroid Eye Disease (TED) adds to the hike in thyroid disorder instances, given it’s a widespread and severe complication of Graves’ disease, thereby escalating the total weight and recognition of thyroid-related illnesses. For instance, as reported by the Canadian Cancer Society, a non-profit, community-focused organization in Canada, in May 2024, around 6,600 novel cases of thyroid cancer are projected to be identified in Canada, with an estimated 280 deaths expected. Consequently, the rise in thyroid disorders is spurring the growth of the thyroid eye disease (TED) market.

Request Your Free Thyroid Eye Disease (TED) Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21300&type=smp

Who Are the Leading Players Fueling Growth in the Thyroid Eye Disease (TED) Market?

Major companies operating in the thyroid eye disease (TED) market are Hoffmann-La Roche AG, Amgen Inc., Genentech Inc., Horizon Therapeutics plc, Pierre Fabre S.A., Innovent Biologics Inc., ACELYRIN Inc., Soleo Health, Zai Lab Limited, HanAll Biopharma Co. Ltd., Tourmaline Bio Inc., Zenas BioPharma Inc., Immunovant Inc., Verana Health, Harbour BioMed (Guangzhou) Co. Ltd., Sling Therapeutics Inc., Crinetics Pharmaceuticals Inc., Lassen Therapeutics Inc., Viridian Therapeutics Inc., Minghui Pharmaceutical Inc.

What Are the Emerging Trends Shaping the Future of the Thyroid Eye Disease (TED) Market?

Main players in the Thyroid Eye Disease (TED) market are targeting innovation in measures like monoclonal antibody therapies, in pursuit of producing more targeted, and consequently effective treatments. These treatments aim to reduce inflammation, improve proptosis, and ultimately better patient outcomes. Monoclonal antibody treatments entail the utilization of laboratory-fabricated antibodies. These antibodies are created to simulate the capacity of the immune system to target and neutralize specific harmful substances or abnormal cells. For instance, in September 2024, Amgen Inc., a biotech firm based in the US, disclosed that TEPEZZA (teprotumumab) received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for treating active TED. TED is an uncommon, potential vision-threatening autoimmune disorder. TEPEZZA is the first and exclusive FDA-approved treatment designed specifically for TED, targeting inflammation reduction, swelling control, and management of other distressing symptoms associated with the disease. This approval is of immense significance to patients in Japan, offering a new and effective alternative for managing TED, an uncommon progressive condition characterized by eye bulging, vision impairment, and eye discomfort.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/thyroid-eye-disease-ted-global-market-report

Which Segments Play a Crucial Role in the Expansion of the Thyroid Eye Disease (TED) Market?

The thyroid eye disease (TED) market covered in this report is segmented –

1) By Treatment Type: Medical, Surgical, Combination Of Medical And Surgical

2) By Disease Severity: Mild, Moderate, Severe

3) By Drug Type: Biologics, Small Molecules, Others Drug Type

4) By Route Of Administration: Oral, Intravenous, Subcutaneous

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Medical: Corticosteroids, Teprotumumab, Antithyroid Medications, Other Medical Treatments

2) By Surgical: Orbital Decompression Surgery, Eyelid Surgery, Strabismus Surgery

3) By Combination Of Medical and Surgical: Combination of Corticosteroids and Orbital Decompression, Combination of Teprotumumab and Eyelid Surgery, Other Combined Approaches

Which Regions Are Driving Growth in the Thyroid Eye Disease (TED) Market?

North America was the largest region in the thyroid eye disease (TED) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid eye disease (TED) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Features of the Thyroid Eye Disease (TED) Market?

Thyroid eye disease (TED), also known as Graves’ Orbitopathy, is an autoimmune condition characterized by inflammation and swelling of the tissues around the eyes, often associated with thyroid disorders. TED can cause symptoms such as bulging eyes, double vision, and eye pain.

Browse Through More Similar Reports By The Business Research Company:

Digestive Enzymes Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digestive-enzyme-global-market-report

Digestive Health Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digestive-health-global-market-report

Digestive Health Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: